诺和诺德:可能缩小与礼来差距的口服减肥药(NYSE:NVO)
· seekingalpha.com
诺和诺德A/S维持买入评级,口服Wegovy需求激增,GLP-1管线强化;2028年市盈率具吸引力,暗示上行空间。点击了解更多关于NVO的信息。
I’m a lifelong entrepreneur who, alongside my other ventures, has always made time for the markets. Driven by genuine passion, I’ve been active with varying...